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Abstract 
We investigated the effects, of cAMP on the urokinase-type lasminogen activator (uPA) production in human pre-B lymphoma cell 
line RC-K8 that is consistently secreting uPA in the conditioned medium. Both Bt2cAMP and PGE1 inhibited the uPA accumulation i  a 
dose-dependent manner. Northern blot analysis and nuclear un-on assay revealed that uPA gene transcription was repressed by Bt2cAMP 
and the repression was negated by inhibition of de novo protein synthesis by cycloheximide. Pretreatment with H89 (N-[2-(p-bromocin- 
namyl-amino) ethyl]-5-isoquinoline sulfonamide), a specific cAMP-dependent protein kinase (PKA) inhibitor, strongly inhibited both the 
PKA activation and the supn~ssion of uPA mRNA accumulation i duced by cAMP. H85 (N-[2-(N-formyl-p-chlorocinnamyl-amino) 
ethyl]-5-isoquinoline sulfonamide), which closely resembles H89 in its chemical structure but is not a selective inhibitor of PKA, showed 
little effect on the regulation of uPA gene regulation by Bt2cAMP. These results suggest that cAMP represses uPA gene transcription in 
human pre-B lymphoma cells through PKA pathway and in which de novo protein synthesis is required. 
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1. Introduction 
Urinary-type plasminogen activator (uPA) was origi- 
nally isolated from urine but has now been found in a 
number of normal and malignant cells, uPA catalyzes the 
conversion of plasminogen to plasmin and plays an impor- 
tant role not only in fibrinclot lysis but in many other 
biological processes uch as cell migration, tissue repair, 
tumor metastasis and inwasion, cAMP is an important 
metabolic effector molecule that controls a variety of 
Abbreviations: uPA, urokinase-type plasminogen activator; Bt2cAMP, 
dibutyryl cAMP; PGE1, prostaglandin El; CHX, cycloheximide; FBS, 
fetal bovine serum; IBMX, 3-isobutyl-l-methylxanthine; PKA, cAMP-de- 
pendent protein kinase; CREB, cAMP-responsive element binding pro- 
tein; CREM, cAMP-responsive-element odulator. 
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cellular processes including the expressions of specific 
genes [1-5]. The regulation of uPA production in both 
normal and malignant cells has been studied especially 
focusing on the participation of cAMP. cAMP stimulates 
uPA production in porcine renal proximal tubule epithelial 
cells (LLC-PK1) [2], mouse granulosa cells [6] and mouse 
mammary carcinoma (SC115) [7], but not in canine renal 
epithelial cells (MDCK) [8]. On the other hand, the effects 
of cAMP on uPA production in human cells are various so 
far. Little effect is observed in HT-1080 human fibrosar- 
coma cells [9], Bowes human melanoma cells [9], T47D 
human mammary carcinoma cells [10], and U-937 human 
histiocytic lymphoma cells [11], while a stimulating effect 
is demonstrated in human cytotrophoblasts [12] and in- 
hibitory effect in human glomerular epithelial cells [8] and 
UCT/gl -1 human glioblastoma cells [9]. 
In screening the cell lines suitable for investigation of 
uPA gene regulation, we found a human pre-B lymphoma 
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Fig. 1. Time course of uPA accumulation i the conditioned medium of 
RC-K8 cultured with or without Bt :cAMP or PGE1. uPA accumulation 
was significantly inhibited by either 1 mM Bt2cAMP or 1 p.M PGE1. 
* * * indicates tatistical difference from corresponding control values, 
P < 0.001. 
accumulation, whereas uPA accumulation was inhibited by 
dexamethasone [17]. These findings led us to investigate 
the effect of cAMP on uPA production in RC-K8 cells. 
cAMP-dependent protein kinase (PKA) appears to be the 
sole mediator of cAMP action in higher eukaryotes [ 18,19]. 
Although many genes are regulated by cAMP, the specific 
mechanism of PKA modulation of gene transcription is not 
fully understood. PKA activated by cAMP phosphorylates 
specific transcriptional factors which subsequently bind to 
specific regulatory sequences in the promoter egions of 
various target genes [20,21]. We provide here the evidence 
that cAMP inhibits the uPA gene transcription through 
PKA pathway in human pre-B lymphoma cells in which de 
novo protein synthesis is required. 
2. Materials and methods 
2.1. Cell culture 
cell line, RC-K8, which is consistently producing uPA in 
the conditioned medium [13]. Intraperitoneal inoculation of 
RC-K8 cells to immunosuppressed newborn hamsters pro- 
duced massive metastatic tumors in the lungs [14]. Inva- 
siveness and metastatic potential of tumor cells appear to 
correlate with their ability to elaborate PA activities, uPA 
catalyzes the conversion of zymogen plasminogen to plas- 
min and then activates tumor cell-derived procollagenase 
[15]. Recent findings suggest hat the uPA receptors ex- 
pressed on the cell-surface localize uPA to cell-cell and 
cell-substratum contact sites [16] 
plasminogen activation may give a 
matastatic advantage to malignant 
interesting to know how uPA gene 
and the cell surface 
specific invasive and 
cells. It is, therefore, 
is regulated in malig- 
nant cells. The addition of phorbol myristate acetate, one 
of the tumor promoters and protein kinase C activators, 
into RC-K8 culture medium resulted in an increase of uPA 
RC-K8 cells were grown in RPMI-1640 culture medium 
supplemented with 10% heat-inactivated fetal bovine 
serum, 100 U/ml penicillin, and 100/xg/ml streptomycin 
as previously described [13]. To examine the effects of 
cAMP and its analogs on uPA production, cells were 
cultured for 3-4 days in serum-free RPMI-1640 medium 
containing various concentrations of cAMP analogs. 
2.2. uPA activity 
uPA activities in conditioned medium were quantita- 
tively measured using a chromogenic substrate S-2444 
(KABI Diagnostica, Stockholm, Sweden) [22]. Briefly, the 
assay was started by adding 50 /zl prewarmed S-2444 (1 
mg/ml) into the wells of 96-well microplate containing 50 
/xl test samples. Increases of absorbance at405 nm during 
20 min were measured using a micro-ELISA-reader. The 
,--, 50 compared with control 
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Fig. 2. Inhibition of uPA accumulation by cAMP analogs. All cAMP analogs examined inhibited uPA accumulation i a dose-dependent manner. Every 
experiment was performed in quadruplicate. *, and * * indicate statistical difference from corresponding control values, P < 0.05, and P < 0.01, 
respectively. 
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results were compared to those of serially diluted standard 
uPA (The Green Cross Corp., Osaka, Japan). 
2.3. RNA preparation and Northern blot analysis 
Total RNAs were isolated by the acid guanidinium 
thiocyanate-phenol-chloroform method [23]. Total RNA 
(10 /zg) was subjected to Northern blot analysis as de- 
scribed [24]. cDNAs for uPA (461 bp for amino acid 
residues 165-301, a gift of The Green Cross Corp., Osaka, 
Japan) and /3actin (Wako Pure Chemicals, Osaka, Japan) 
were labeled with [32 P]dCTP by the random primer method. 
mRNA levels were quantitatively measured by counting 
the radioactivity using the Radioanalytic Imaging System 
AMBIS TM (AMBIS Systeras, San Diego, USA). Some 
experiments were performed by dot blotting technique 
using Bio-Dot ® SF Blotting; apparatus (Bio-Rad). 
2.4. Nuclear run-on transcription 
Nuclei were prepared from 5 X 10 7 cells treated with 1 
mM Bt2cAMP and/or 10 /xg/ml cycloheximide (CHX), 
and nuclear un-on assays were performed by the method 
described by Greenberg and Ziff [25]. An equal amount of 
labeled RNA from each sample was hybridized to the 
linearized pUC19-plasmids carrying uPA and /3actin cD- 
NAs (5 /xg each/slot) which were transferred onto Hy- 
bond-N ® filter (Amersham) by the slot blot technique. The 
amount of transcripts was determined by counting the 
radioactivity using AMBIS as described above. 
2.5. Detection and quantitation of the PKA activities in 
RC-K8 cells after stimulation with Bt e AMP and PGE1 
PKA activities in cell lysates were measured by a 
non-radioactive method which was developed by Promega 
(Madison, WI, USA). Cells after stimulation with 
Bt2cAMP or PGE1 were washed with PBS and resus- 
uPA 
13aclin 
pUCI9 
Bt2cAMP Control Bt2eAMP CltX 
+ CIIX 
Fig. 4. Effects of Bt2cAMP and CHX on uPA gene transcription. RC-K8 
cells were treated with 1 mM Bt2cAMP with or without 10/xg/ml CHX 
for 5 h. uPA and /3actin (control) gene transcription rates were assessed 
by nuclear un-on assay as described in sECTION 2. Labeled RNAs were 
hybridized to the linearized plasmids (pUC19) carrying uPA and flactin 
cDNAs. 
pended in an original volume of the cell lysis buffer (150 
mM Tris-HC1 [pH 7.5], 0.5 mM EDTA, 0.5 mM EGTA, 
10 mM 2-mercaptoethanol, 20 ~g/ml  leupeptin, 0.5m M 
PMSF, 0.5% Triton X-100). Reaction mixtures containing 
10 /zl of cell lysate, 5 p,1 of each ATP, PepTag TM A1 
peptide and 5 X reaction buffer were incubated for 30 min 
at 30°C. Phosphorylated peptides in the mixtures were 
separated from non-phosphorylated peptides by agarose 
gel electrophoresis a described in the manufacturer's in-
struction. To measure the PKA activities in RC-K8 cells, 
at a minimum 200 /zM (final concentration) ATP was 
necessary to obtain the reproducible results. We therefore 
used 200/zM ATP in the subsequent experiments. Quanti- 
tation of protein kinase activities was accomplished by a 
spectrofluorometer (Shimadzu, Kyoto, Japan). Negatively 
charged phosphorylated bands were excised from the gel 
and melted as described in the instruction manual. Melted 
gels were diluted with 2.5 ml distilled water, and the 
percentage of the intensity of the emission wavelength at 
592 nm was measured using the spectrofluorometer with 
the excitation wavelength at 568 nm. It was not easy to 
28S ~- 
18S 
uPA 
13-actin 
N 
0 2 5 9 24 9~ 0 2 5 9 24 (hr) 
I l '~  I I 
Bt,cAMP (lmM) ~ PGE1 (I/¢M) 
Fig. 3. Time course of uPA gene expression regulated by Bt2cAMP or PGE1. This is a representative result out of three Northern blot analyses. The blot 
was first hybridized with an uPA cDNA probe and subsequently h bridized with a /3actin cDNA probe to control for RNA loading. 
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Fig. 5. Dose-dependent stimulating effects of BtEcAMP (A) and PGE1 (B) on the protein kinase activity in RC-K8 cells. Cells were cultured in 
RPMI-1640 containing various concentrations of BtEcAMP (0.5-5 mM) or PGE1 (1-1000 nM) for 30 min. The mean and range of duplicate values are 
shown in this figure. 
calculate the absolute PKA units in cell lysates, since 
sometimes PKA-standard included in the kit did not show 
proper PKA activities. Therefore, we expressed PKA activ- 
ities in relative values. 
2.6. Statistical analysis 
Statistical analysis was done on Macintosh Ilsi (Apple 
Computers, Cupertino, CA). The results were expressed as 
mean _ 1 standard eviation of the mean. Statistical signif- 
icant was determined by Student t-test to compare un- 
paired data. 
3. Results 
3.1. Effects of  reagents which raise intracellular cAMP on 
uPA accumulation in RC-K8 conditioned medium 
Effects of  cAMP analogs including BtEcAMP and 8- 
bromo cAMP (membrane permeable cAMPs),  forskolin 
60 
~" 5O 
,~ 40 
,~  
30 °m 
20 
.~  
I0  
u 
+ 
control 3° -  - -4°  - - ? ° -  - P - - 4° -  - - 5°  -1- -3°  - - 4° -  - -5°  [ 
H89 H7 H8 
Concentrations of  inhibitors (~M) 
Fig. 6. Inhibitory effects of H89, H7 and H8 on Bt2cAMP-induced protein kinase activation in RC-K8 cells. The inset is a representative photograph of the 
gel under UV light. The first well from the left in the inset indicates the protein kinase activity in the control cells. The activity was undetectable and 
therefore xcluded in this histogram. Emission intensities are plotted as a histogram derived from spectrofluorometric analysis of the phosphorylated bands 
in samples of corresponding wells in the inset. The mean and range of duplicated values are shown in this figure. 
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and PGE1 which raise intracellular cAMP by stimulating 
adenylate cyclase, and 3-isobutyl- l-methylxanthine 
(IBMX) which raises intracellular cAMP by inhibiting 
phosphodiesterase on uPA accumulation i  RC-K8 condi- 
tioned medium were investigated. As shown in Fig. 1, uPA 
activities were gradually itncreased in the conditioned 
medium. Both 1 mM Bt2cAMP and 1 /xM PGE1 inhibited 
the uPA accumulation. The cell viability was not signifi- 
cantly changed during those treatments. Other cAMP 
analogs also inhibited the uPA accumulation i a dose-de- 
pendent manner (Fig. 2). 
3.2. Effects of  Bt2cAMP and PGE1 on uPA mRNA levels 
and uPA gene transcription 
Northern blot analysis was performed to define the 
mechanisum by which cAMP inhibits uPA accumulation. 
uPA gene was constitutively expressed in RC-K8 cells. 
After stimulation with either Bt2cAMP or PGE1, uPA 
mRNA levels were transiently increased and then rapidly 
decreased below the control levels (Fig. 3). Nuclear run-on 
assay demonstrated that cAMP repressed the uPA gene 
transcription and the repression was inhibited by CHX 
(Fig. 4). These data suggest hat the down-regulation of 
uPA production by cAMP has resulted from repression of 
the gene transcription and in which de novo protein syn- 
thesis is required. 
3.3. Effect o f  H89 on Bt2cAMP-and PGEl- induced PKA 
activation in RC-K8 cells 
Both Bt2cAMP and PGE1 rapidly induced PKA activa- 
tion in RC-K8 cells in a dose-dependent manner (Fig. 5). 
To investigate whether the repression of uPA gene tran- 
scription by Bt2cAMP is through PKA pathway, we used a 
strong PKA inhibitor, H89 [26]. RC-K8 cells were cultured 
in RPMI-1640 containing H89 (10-50 /xM) for 1 h. Then 
the culture medium was replaced by a fresh medium 
containing both H89 and Bt2cAMP (2.5 mM) and further 
incubated for 30 min. H89 inhibited the Bt2cAMP-induced 
PKA activation in a dose-dependent manner. More than 30 
/~M H89 almost completely inhibited the PKA activation 
by Bt2cAMP (Fig. 6). Pretreatment with H85 (30-50/~M) 
did not inhibit the Bt2cAMP-induced PKA activation (data 
A 
H89 
B 
H85 
C 
H7 
cAMP 
+ - + - + + 
uPA 
[ actin 
+ - + - + ÷ 
uPA 
I actin 
+ + - + + 
uPA 
[3actin 
- - 4- + - - + + 
1 2 3 4 5 6 7 8 
I I I I 
2 h 9h 
Fig. 7. Effects of H89, H85 or H7 on the uPA gene regulation by cAMP. Shown is Northern blots of uPA and flactin mRNAs. The cells were treated with 
2.5 mM Bt2cAMP (lanes 3, 4, 7 and 9) in the presence of30 p.M of H89 (lanes 2, 4, 6 and 8 in panel A), H85 (lanes 2, 4, 6 and 8 in panel B) or H7 (lanes 
2, 4, 6 and 8 in panel C), After 2 and 9 h, total RNA was isolated and subjected toNorthern blot analysis. This is a representative result out of three 
experiments. 
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not shown), and other protein kinase inhibitors including 
H7 and H8 only slightly inhibited activity (Fig. 6). 
3.4. Effects of H89, H85 and H7 on Bt2cAMP-induced 
uPA gene regulation 
Effects of these protein kinase inhibitors on the 
Bt2cAMP-induced uPA gene regulation were investigated 
by Northern blot technique. The inhibition of uPA mRNA 
accumulation was negated by pretreatment with 30 /zM 
H89 but not the transient induction (Fig. 7A). Neither H85 
(30 /zM) nor H7 (30 /zM) showed any effect (Fig. 7B,C). 
Taken together, these results strongly suggest that the 
repression of uPA gene transcription by cAMP is through 
PKA pathway. 
4. Discussion 
Our results clearly indicate that cAMP down-regulates 
uPA production in human pre-B lymphoma cells by in- 
hibiting the gene transcription. However, previous reports 
have shown that cAMP has a rather stimulating effect on 
uPA production. The mechanism of cAMP-induced uPA 
gene expression i  LLC-PKI porcine kidney cell has been 
extensively investigated by Nagamine and his group. They 
reported that the induction of uPA by cAMP occurs through 
the activation of PKA [27]. They identified a cAMP-re- 
sponsive region in 3.4 kb upstream of the transcription 
initiation site, in which a sequence (TGACG) homologous 
to a consensus cAMP-response element (CRE; 
TGACGTCA) [28] was included. Protein-protein terac- 
tion on these domains would play an important role in 
mediating cAMP action on uPA gene induction [28]. Simi- 
lar inducing effects by cAMP are observed in other animal 
cells [6,7]. Moreover, inhibition of protein synthesis has 
resulted in an increase of uPA mRNA stability in LLC-PK1 
and protein synthesis is not necessary in the induction of 
uPA gene by 8-bromo cAMP [2,29]. The increase of uPA 
mRNA after stimulation with 8-bromo cAMP was main- 
tained in LLC-PK1. In contrast to these previous reports, 
the increase in uPA mRNA by either Bt2cAMP or PGE1 is 
only transient in RC-K8 cells as shown in Fig. 3. Interest- 
ingly, cAMP rather down-regulates uPA production by 
repressing the gene transcription in RC-K8 cells and in 
which de novo protein synthesis i  required. Moreover, the 
down-regulation appears to be through PKA pathway. 
We did not check the effects of H89 on the direct 
protein phosphorylation i duced by Bt2cAMP, but the 
protein phosphorylation might be inhibited by H89 since 
H89 (30 /zM) clearly inhibited the protein kinase activa- 
tion by Bt2cAMP. H89 is the strongest PKA inhibitor 
among synthetic kinase inhibitors in vitro, but the discrep- 
ancy regarding the effective dose of H89 in vitro and in 
vivo is pointed out in the paper [26]. In fact, only high 
concentrations (more than 20 /zM) of H89 strongly inhib- 
ited the PKA activation by Bt2cAMP in RC-K8 cells. H89 
has been shown to inhibit the protein kinase activity 
competitively with ATP. Therefore, H89 only when per- 
meated into the cells can exert he inhibition. Other kinase 
inhibitors H7 and H8 showed little effect on uPA gene 
regulation by BtzcAMP. H7 (30 /zM) inhibited phorbol 
myristate acetate (PMA)-induced uPA gene expression in 
the cells (unpublished data). PMA is shown to be a protein 
kinase C activator. Therefore, we consider that the effect 
of H89 on the BtzcAMP-induced repression of uPA gene 
transcription has resulted from the specific inhibitory ef- 
fect on the Bt2cAMP-induced PKA activation. 
PKA in eukaryotes exists as two isoenzymes (type I and 
II), both of which consist of a tetrameric holoenzyme 
composed of two regulatory and two catalytic subunits. 
Catalytic subunits released upon activation will phospho- 
rylate transcriptonal factors such as cAMP-responsive ele- 
ment binding protein (CREB) which binds to a specific 
motif (CRE) in the promoter region of the gene [4,30,31]. 
Virtually all of the evidence available to date supports the 
role of catalytic subunits of the protein kinase as the 
proximal intermediate in the effect of cAMP on gene 
transcription [32]. The most direct experimental evidence 
supporting an effect of the catalytic subunits on the uPA 
gene transcription is demonstrated byNakagawa et al. [33]. 
However, the correlation between PKA activation and the 
down-regulation of uPA production after stimulation by 
BtzcAMP suggests that PKA catalytic subunits are impli- 
cated in the down-regulation process in RC-K8 cells. This 
conclusion is supported by the obvious inhibitory effect of 
H89 on the down-regulation of uPA gene expression by 
Bt2cAMP. Recent studies have identified different iso- 
forms of the CREB. Among them, cAMP-responsive-ele- 
ment modulator (CREM) isoforms appear to regulate 
CRE-mediated transcription i both positive and negative 
manners [34]. Therefore, one of them would be phospho- 
rylated and activated after cAMP-stimulation in RC-K8 
cells and might act as a repressor on uPA gene expression. 
The CREM products how extensive homology with tran- 
scriptional factor CREB and can block the transcriptional 
activation by CREB [35]. 
Our results suggest hat the phosphorylated protein(s) 
may be implicated in the down-regulation of uPA gene 
expression by cAMP and the protein kinase activity-inde- 
pendent mechanism ay be involved in the transient in- 
duction of uPA gene expression. In any case, RC-K8 is a 
valuable cell line to study these complex mechanisms of 
the uPA gene regulation by cAMP. 
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